Targeted Catalytic Inactivation
of Angiotensin Converting
Enzyme by Lisinopril-Coupled Transition-Metal Chelates
- Publication date
- Publisher
Abstract
A series of compounds that target reactive transition-metal
chelates
to somatic angiotensin converting enzyme (sACE-1) have been synthesized.
Half-maximal inhibitory concentrations (IC<sub>50</sub>) and rate
constants for both inactivation and cleavage of full-length sACE-1
have been determined and evaluated in terms of metal chelate size,
charge, reduction potential, coordination unsaturation, and coreactant
selectivity. Ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic
acid (NTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA), and tripeptide GGH were linked to the lysine side chain of
lisinopril by 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride/<i>N</i>-hydroxysuccinimide coupling. The resulting amide-linked
chelate–lisinopril (EDTA–lisinopril, NTA–lisinopril,
DOTA–lisinopril, and GGH–lisinopril) conjugates were
used to form coordination complexes with iron, cobalt, nickel, and
copper, such that lisinopril could mediate localization of the reactive
metal chelates to sACE-1. ACE activity was assayed by monitoring cleavage
of the fluorogenic substrate Mca-RPPGFSAFK(Dnp)-OH, a derivative of
bradykinin, following preincubation with metal chelate–lisinopril
compounds. Concentration-dependent inhibition of sACE-1 by metal chelate–lisinopril
complexes revealed IC<sub>50</sub> values ranging from 44 to 4500
nM for Ni–NTA–lisinopril and Ni–DOTA–lisinopril,
respectively, versus 1.9 nM for lisinopril. Stronger inhibition was
correlated with smaller size and lower negative charge of the attached
metal chelates. Time-dependent inactivation of sACE-1 by metal chelate–lisinopril
complexes revealed a remarkable range of catalytic activities, with
second-order rate constants as high as 150 000 M<sup>–1</sup> min<sup>–1</sup> (Cu–GGH–lisinopril), while
catalyst-mediated cleavage of sACE-1 typically occurred at much lower
rates, indicating that inactivation arose primarily from side chain
modification. Optimal inactivation of sACE-1 was observed when the
reduction potential for the metal center was poised near 1000 mV,
reflecting the difficulty of protein oxidation. This class of metal
chelate–lisinopril complexes possesses a range of high-affinity
binding to ACE, introduces the advantage of irreversible catalytic
turnover, and marks an important step toward the development of multiple-turnover
drugs for selective inactivation of sACE-1